Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma.

Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy... To describe three patients with secondary leukemia after treatment with 131I-metaiodobenzylguanidine (MIBG) for neuroblastoma. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of pediatric hematology/oncology Pubmed

Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma.

Journal of pediatric hematology/oncology , Volume 25 (7): -535 – Aug 20, 2003

Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma.


Abstract

To describe three patients with secondary leukemia after treatment with 131I-metaiodobenzylguanidine (MIBG) for neuroblastoma.

Loading next page...
 
/lp/pubmed/secondary-myelodysplastic-syndrome-and-leukemia-following-131i-dGQHoPKX3z

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1077-4114
DOI
10.1097/00043426-200307000-00009
pmid
12847321

Abstract

To describe three patients with secondary leukemia after treatment with 131I-metaiodobenzylguanidine (MIBG) for neuroblastoma.

Journal

Journal of pediatric hematology/oncologyPubmed

Published: Aug 20, 2003

There are no references for this article.